Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PCNA | P12004 | 6/20 | 0.67 |
| ▸ | THRB | P10828 | 9/20 | 0.52 |
| ▸ | THRA | P10827 | 6/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | PPARG | P37231 | 3/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | GABRP | O00591 | 1/20 | 0.52 |
| ▸ | GABRD | O14764 | 1/20 | 0.52 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.52 |
| ▸ | F2 | P00734 | 1/20 | 0.52 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.52 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.52 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.52 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.52 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.52 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34943 | 0.96 | PCNA (0.71) | PCNATHRBTHRALMNAMEN1 | |
| SCHEMBL31368013 | 0.96 | PCNA (0.71) | PCNATHRBTHRALMNAMEN1 | |
| SCHEMBL5501440 | 0.95 | PCNA (0.70) | PCNATHRBTHRALMNAMEN1 | |
| SCHEMBL2679290 | 0.95 | PCNA (0.70) | PCNATHRBTHRALMNAMEN1 | |
| Sulfuric Acid SCHEMBL8910589 | 0.84 | PCNA (0.60) | PCNATHRBTHRALMNAMEN1 | |
| SCHEMBL428139 | 0.80 | PCNA (1.00) | PCNATHRBTHRALMNAMEN1 | |
| SCHEMBL1487713 | 0.80 | PCNA (1.00) | PCNATHRBTHRALMNAMEN1 | |
| SCHEMBL445767 | 0.80 | PCNA (1.00) | PCNATHRBTHRALMNAMEN1 | |
| SCHEMBL4926016 | 0.80 | PCNA (0.52) | PCNATHRBTHRALMNAMEN1 | |
| SCHEMBL1115191 | 0.80 | PCNA (0.52) | PCNATHRBTHRALMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240165064-A1 | LONG-LASTING RESORBABLE SUBCUTANEOUS IMPLANT WITH PROLONGED RELEASE OF PRE-CONCENTRATED PHARMACOLOGICALLY ACTIVE SUBSTANCE IN POLYMER FOR THE TREATMENT OF HYPOTHYROIDISM, AND METHOD | PERACCHI EDSON LUIZ (BR) | 2024-05-23 | — | — | US | claimed |
| EP-4316464-A1 | LONG-LASTING RESORBABLE SUBCUTANEOUS IMPLANT WITH PROLONGED RELEASE OF PRE-CONCENTRATED PHARMACOLOGICALLY ACTIVE SUBSTANCE IN POLYMER FOR THE TREATMENT OF HYPOTHYROIDISM, AND METHOD | Peracchi, Edson Luiz (BR) | 2024-02-07 | — | — | EP | claimed |
| WO-2022204771-A1 | LONG-LASTING RESORBABLE SUBCUTANEOUS IMPLANT WITH PROLONGED RELEASE OF PRE-CONCENTRATED PHARMACOLOGICALLY ACTIVE SUBSTANCE IN POLYMER FOR THE TREATMENT OF HYPOTHYROIDISM, AND METHOD | PERACCHI EDSON LUIZ (BR) | 2022-10-06 | — | — | WO | claimed |
| US-10238615-B2 | 3,5,3′-triiodothyronine sulfate as thyromimetic agent and pharmaceutical formulations thereof | BRACCO S.P.A. (IT) | 2019-03-26 | — | — | US | claimed |
| US-9012438-B2 | 3,5,3′ -triiodothronine sulfate as thyromimetic agent and pharmaceutical formulations thereof | BRACCO S.P.A. (IT) | 2015-04-21 | — | — | US | claimed |
| EP-1767202-A1 | 3,5,3'-Triiodothyronine sulfate as thyromimetic agent and pharmaceutical formulations thereof | BRACCO S.p.A. (IT) | 2007-03-28 | — | — | EP | claimed |
| EP-1560575-B1 | 3,5,3'-TRIIODOTHYRONINE SULFATE AS THYROMIMETIC AGENT AND PHARMACEUTICAL FORMULATIONS THEREOF | BRACCO SPA (IT) | 2006-09-27 | — | — | EP | claimed |
| US-20050272816-A1 | 3,5,3' -triiodothronine sulfate as thyromimetic agent and pharmaceutical formulations thereof | BRACCO S.P.A. (IT) | 2005-12-08 | — | — | US | claimed |
| EP-1560575-A1 | 3,5,3'-TRIIODOTHYRONINE SULFATE AS THYROMIMETIC AGENT AND PHARMACEUTICAL FORMULATIONS THEREOF | BRACCO S.p.A. (IT) | 2005-08-10 | — | — | EP | claimed |
| WO-2004043452-A1 | 3,5,3’-TRIIODOTHYRONINE SULFATE AS THYROMIMETIC AGENT AND PHARMACEUTICAL FORMULATIONS THEREOF | BRACCO S.P.A. (IT) | 2004-05-27 | — | — | WO | claimed |
| US-20240165064-A1 | LONG-LASTING RESORBABLE SUBCUTANEOUS IMPLANT WITH PROLONGED RELEASE OF PRE-CONCENTRATED PHARMACOLOGICALLY ACTIVE SUBSTANCE IN POLYMER FOR THE TREATMENT OF HYPOTHYROIDISM, AND METHOD | PERACCHI EDSON LUIZ (BR) | 2024-05-23 | — | — | US | disclosed |
| US-20240165064-A1 | LONG-LASTING RESORBABLE SUBCUTANEOUS IMPLANT WITH PROLONGED RELEASE OF PRE-CONCENTRATED PHARMACOLOGICALLY ACTIVE SUBSTANCE IN POLYMER FOR THE TREATMENT OF HYPOTHYROIDISM, AND METHOD | PERACCHI EDSON LUIZ (BR) | 2024-05-23 | — | — | US | disclosed |
| EP-4316464-A1 | LONG-LASTING RESORBABLE SUBCUTANEOUS IMPLANT WITH PROLONGED RELEASE OF PRE-CONCENTRATED PHARMACOLOGICALLY ACTIVE SUBSTANCE IN POLYMER FOR THE TREATMENT OF HYPOTHYROIDISM, AND METHOD | Peracchi, Edson Luiz (BR) | 2024-02-07 | — | — | EP | disclosed |
| EP-4316464-A1 | LONG-LASTING RESORBABLE SUBCUTANEOUS IMPLANT WITH PROLONGED RELEASE OF PRE-CONCENTRATED PHARMACOLOGICALLY ACTIVE SUBSTANCE IN POLYMER FOR THE TREATMENT OF HYPOTHYROIDISM, AND METHOD | Peracchi, Edson Luiz (BR) | 2024-02-07 | — | — | EP | disclosed |
| WO-2022204771-A1 | LONG-LASTING RESORBABLE SUBCUTANEOUS IMPLANT WITH PROLONGED RELEASE OF PRE-CONCENTRATED PHARMACOLOGICALLY ACTIVE SUBSTANCE IN POLYMER FOR THE TREATMENT OF HYPOTHYROIDISM, AND METHOD | PERACCHI EDSON LUIZ (BR) | 2022-10-06 | — | — | WO | disclosed |
| EP-1560575-A1 | 3,5,3'-TRIIODOTHYRONINE SULFATE AS THYROMIMETIC AGENT AND PHARMACEUTICAL FORMULATIONS THEREOF | BRACCO S.p.A. (IT) | 2005-08-10 | — | — | EP | disclosed |
| EP-1560575-A1 | 3,5,3'-TRIIODOTHYRONINE SULFATE AS THYROMIMETIC AGENT AND PHARMACEUTICAL FORMULATIONS THEREOF | BRACCO S.p.A. (IT) | 2005-08-10 | — | — | EP | disclosed |
| WO-2004043452-A1 | 3,5,3’-TRIIODOTHYRONINE SULFATE AS THYROMIMETIC AGENT AND PHARMACEUTICAL FORMULATIONS THEREOF | BRACCO S.P.A. (IT) | 2004-05-27 | — | — | WO | disclosed |
| WO-2004043452-A1 | 3,5,3’-TRIIODOTHYRONINE SULFATE AS THYROMIMETIC AGENT AND PHARMACEUTICAL FORMULATIONS THEREOF | BRACCO S.P.A. (IT) | 2004-05-27 | — | — | WO | disclosed |
| US-5670380-A | QUANTITATIVE ANALYSIS OF PREGNANT WOMEN | VETERANS AFFAIRS, DEPARTMENT OF | 1997-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10238615-B2 | 3,5,3′-triiodothyronine sulfate as thyromimetic agent and pharmaceutical formulations thereof | TPO, THRA, THRB | PCNA 4864/4885THRB 3/4885THRA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.